{ "schemaVersion": "1.0.0", "datasetVersion": "2.3.0", "dataset": "vaccine-product-registry", "generatedFrom": "https://antivaxxare.se", "license": "UNKNOWN – återanvändning av underliggande källmaterial styrs av respektive utgivare.", "notice": "Identitetsfälten (key, name, conceptKey) kommer ur canonical_vaccine_product via en genererad projektion, inte ur en handunderhållen fil. URL är route-mappning, inte identitet. Att produkten finns här betyder inte att den ingår i det svenska programmet, är tillgänglig eller är godkänd i Sverige – det är tre skilda dimensioner. datasetVersion 2.1.0: projection redovisar nu källa och readiness-status per fältfamilj. projection.documents.canonical är dokument som är bundna till produkten via SourceVersion i kanonisk persistens; projection.documents.legacyCompatibility är äldre åtkomstlänkar som inte är kanonisk proveniens. summary är redaktionell text, inte källfakta. programmeUse är blockerad semantiskt och säger ingenting om svensk programanvändning. datasetVersion 2.2.0: projection.canonicalFacts är strukturerade fakta ur aktuell produktresumé, varje rad bunden till en hashad källversion, ett exakt citatmål och en observerad myndighetsversion. currentnessStatus säger endast om myndighetens version matchar den vi läste – det är inte källverifiering, inte evidensgradering och inte medicinsk granskning. authorised_indication är regulatorisk indikation, inte svensk programrekommendation. Värden återges på källans språk; ingen översättning genereras. datasetVersion 2.3.0: projection.programmeUse är borttagen och ersatt av projection.programme, som håller isär tre saker – kategoriinklusion i gällande programversion, beslutad framtida programstart och produktnivå. Produktnivå sätts endast när en aktuell officiell källa uttryckligen namnger produkten; kategoriinklusion är aldrig bevis för ett handelsnamn, och avsaknad av källa redovisas som ej fastställd, aldrig som att produkten inte används.", "count": 11, "identityProjection": { "sourceReadModel": "canonical_public_vaccine_product", "generatedAt": "2026-09-03T11:29:57.714Z", "recordCount": 11, "fingerprint": "fnv1a32:3d4077ab", "note": "Projektion av canonical_vaccine_product. Fingeravtrycket identifierar exakt vilken identitetsmängd exporten byggdes av; det är inte en kvalitets- eller sanningsuppgift." }, "items": [ { "id": "product:cervarix", "key": "cervarix", "name": "Cervarix", "conceptKey": "hpv", "conceptName": "Vaccin mot humant papillomvirus", "atcCode": null, "authorisationStatus": null, "identitySource": "canonical_vaccine_product", "url": "https://antivaxxare.se/vacciner/cervarix", "canonicalUrl": "https://antivaxxare.se/vacciner/cervarix", "projection": { "note": "Fälten nedan är presentation, inte kanonisk identitet. Varje fältfamilj bär sin egen källa och readiness-status (RUN 11.5).", "summary": { "value": "Tvåvalent HPV-vaccin mot typ 16 och 18 med AS04-adjuvans. Produkten är den som prövades i PATRICIA-studien, där kontrollgruppen fick hepatit A-vaccin.", "source": "editorial", "status": "EDITORIAL_ONLY" }, "programme": { "source": "canonical", "status": "CANONICAL_READY", "productLevelStatus": "CATEGORY_INCLUDED_PRODUCT_NOT_ESTABLISHED", "productLevelStatusLabel": "Ingår i programkategori — produktnivå ej fastställd", "currentness": "currentness-verified", "note": "Att begreppet ingår i programmet är inte ett belägg för att just denna handelsprodukt används. Vi har ingen aktuell officiell källa på produktnivå. Uppgiften redovisas som ej fastställd — inte som att produkten inte används.", "currentCategories": [ { "categoryKey": "hpv", "label": "HPV (humant papillomvirus)", "inclusion": "included", "programVersion": "se-barn-2026", "validFrom": "2026-01-01", "schedule": [ { "dosePosition": 1, "ageGroup": "Årskurs 5", "gradeBased": true }, { "dosePosition": 2, "ageGroup": "Årskurs 5", "gradeBased": true } ], "sourceKey": "fhm-barnvaccinationsprogram-oversikt", "sourceUrl": "https://www.folkhalsomyndigheten.se/vara-amnesomraden/vaccinationer/nationella-vaccinationsprogram/barnvaccinationsprogram/", "contentHash": "cd28f32b64c44642ae7db48259abe6c4160df042cfca6e84f6400f52c155ec10", "citationTarget": "Schematabell, rad \"HPV (Humant papillomvirus)\"", "currentness": "currentness-verified" } ], "futureCategories": [], "productLevelEvidence": null }, "regulatoryIndication": { "value": "Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types. See sections 4.4 and 5.1 for important information on the data that support this indication. The use of Cervarix should be in accordance with official recommendations.", "language": "en", "source": "canonical", "status": "CANONICAL_READY" }, "canonicalFacts": { "source": "canonical", "status": "CANONICAL_READY", "readyCount": 4, "blockedCount": 0, "rows": [ { "factType": "atc_code", "value": "J07BM02", "language": "en", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "ema:eu-epar-product-information:cervarix", "sourceUrl": "https://www.ema.europa.eu/en/documents/product-information/cervarix-epar-product-information_en.pdf", "contentHash": "8e78cfc800f6b86680049fde9db1c0789745d8e471cb04fab12f5a34fdc1917a", "citationTarget": "section:5.1", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "revision:43", "observedVersionIdentifier": "revision:43", "currentnessObservedAt": "2026-09-01T12:04:22.093+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "authorised_indication", "value": "Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types. See sections 4.4 and 5.1 for important information on the data that support this indication. The use of Cervarix should be in accordance with official recommendations.", "language": "en", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "ema:eu-epar-product-information:cervarix", "sourceUrl": "https://www.ema.europa.eu/en/documents/product-information/cervarix-epar-product-information_en.pdf", "contentHash": "8e78cfc800f6b86680049fde9db1c0789745d8e471cb04fab12f5a34fdc1917a", "citationTarget": "section:4.1", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "revision:43", "observedVersionIdentifier": "revision:43", "currentnessObservedAt": "2026-09-01T12:04:22.093+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "marketing_authorisation_holder", "value": "GlaxoSmithKline Biologicals SA. Rue de l'Institut 89 B-1330 Rixensart, Belgium", "language": "en", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "ema:eu-epar-product-information:cervarix", "sourceUrl": "https://www.ema.europa.eu/en/documents/product-information/cervarix-epar-product-information_en.pdf", "contentHash": "8e78cfc800f6b86680049fde9db1c0789745d8e471cb04fab12f5a34fdc1917a", "citationTarget": "section:7", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "revision:43", "observedVersionIdentifier": "revision:43", "currentnessObservedAt": "2026-09-01T12:04:22.093+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "pharmaceutical_form", "value": "Suspension for injection. Turbid white suspension.", "language": "en", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "ema:eu-epar-product-information:cervarix", "sourceUrl": "https://www.ema.europa.eu/en/documents/product-information/cervarix-epar-product-information_en.pdf", "contentHash": "8e78cfc800f6b86680049fde9db1c0789745d8e471cb04fab12f5a34fdc1917a", "citationTarget": "section:3", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "revision:43", "observedVersionIdentifier": "revision:43", "currentnessObservedAt": "2026-09-01T12:04:22.093+00:00", "sourceVerificationStatus": "unverified" } ] }, "documents": { "source": "canonical", "status": "CANONICAL_READY", "canonical": [ { "sourceKey": "ema:cervarix-produktinformation", "name": "EMA – Cervarix, produktinformation (EPAR)", "publisher": "European Medicines Agency", "url": "https://www.ema.europa.eu/en/documents/product-information/cervarix-epar-product-information_en.pdf", "retrievedAt": "2026-09-01T06:50:56.071793+00:00", "contentHash": "8e78cfc800f6b86680049fde9db1c0789745d8e471cb04fab12f5a34fdc1917a", "sourceVerificationStatus": "unverified", "citationTargets": [ "section:2", "section:6.1" ] } ], "legacyCompatibility": [ { "label": "EMA EPAR – Cervarix, produktinformation", "url": "https://www.ema.europa.eu/en/documents/product-information/cervarix-epar-product-information_sv.pdf" } ] }, "fieldMatrix": [ { "field": "identity", "layer": "identity", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "summary", "layer": "editorial", "source": "editorial", "status": "EDITORIAL_ONLY", "blocker": null }, { "field": "facts", "layer": "structured-fact", "source": "legacy-compatibility", "status": "LEGACY_COMPATIBILITY", "blocker": "Kvarvarande legacy-rader saknar ännu en kanonisk faktarad bunden till SourceVersion + CitationTarget. De behåller sin egen fältkälla och promotas inte." }, { "field": "canonicalFacts", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "regulatoryIndication", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "documents", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "programme", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "publication", "layer": "publication-policy", "source": "editorial", "status": "EDITORIAL_ONLY", "blocker": null } ] } }, { "id": "product:gardasil-9", "key": "gardasil-9", "name": "Gardasil 9", "conceptKey": "hpv", "conceptName": "Vaccin mot humant papillomvirus", "atcCode": null, "authorisationStatus": null, "identitySource": "canonical_vaccine_product", "url": "https://antivaxxare.se/vacciner/gardasil-9", "canonicalUrl": "https://antivaxxare.se/vacciner/gardasil-9", "projection": { "note": "Fälten nedan är presentation, inte kanonisk identitet. Varje fältfamilj bär sin egen källa och readiness-status (RUN 11.5).", "summary": { "value": "Nio-valent rekombinant HPV-vaccin. Produkten är centralt godkänd i EU och har en egen produktresumé hos EMA.", "source": "editorial", "status": "EDITORIAL_ONLY" }, "programme": { "source": "canonical", "status": "CANONICAL_READY", "productLevelStatus": "EXPLICIT_PROCURED_PRODUCT", "productLevelStatusLabel": "Upphandlad produkt för det allmänna programmet", "currentness": "currentness-verified", "note": "Upphandling är en egen dimension. Uppgiften säger vad som är upphandlat vid källans versionstidpunkt, inte att produkten är medicinskt bättre eller att den alltid kommer att användas.", "currentCategories": [ { "categoryKey": "hpv", "label": "HPV (humant papillomvirus)", "inclusion": "included", "programVersion": "se-barn-2026", "validFrom": "2026-01-01", "schedule": [ { "dosePosition": 1, "ageGroup": "Årskurs 5", "gradeBased": true }, { "dosePosition": 2, "ageGroup": "Årskurs 5", "gradeBased": true } ], "sourceKey": "fhm-barnvaccinationsprogram-oversikt", "sourceUrl": "https://www.folkhalsomyndigheten.se/vara-amnesomraden/vaccinationer/nationella-vaccinationsprogram/barnvaccinationsprogram/", "contentHash": "cd28f32b64c44642ae7db48259abe6c4160df042cfca6e84f6400f52c155ec10", "citationTarget": "Schematabell, rad \"HPV (Humant papillomvirus)\"", "currentness": "currentness-verified" } ], "futureCategories": [], "productLevelEvidence": { "sourceKey": "fhm-hpv-utbildning-elevhalsan", "sourceName": "Vaccination mot HPV — en utbildning för personal inom elevhälsan", "sourceUrl": "https://www.folkhalsomyndigheten.se/contentassets/6943e15357444cb0a8538c8c98497ca0/vaccination-mot-hpv-en-utbildning-for-personal-inom-elevhalsan.pdf", "retrievedAt": "2026-09-01T12:19:05Z", "contentHash": "332961edb86583ae05bf4070ce7d1821d664c82174b50140a891cd5df021415b", "citationTarget": "Avsnitt \"Omfattning av barnvaccinationsprogrammet\", punktlista", "quote": "För närvarande är Gardasil 9 upphandlat för det allmänna vaccinationsprogrammet i Sverige.", "authorityVersionIdentifier": "Uppdaterad mars 2026; Last-Modified 2026-03-16", "currentness": "currentness-verified" } }, "regulatoryIndication": { "value": "Gardasil 9 är indicerat för aktiv immunisering av individer från 9 års ålder mot följande HPV- sjukdomar: • premaligna lesioner och cancer som påverkar cervix, vulva, vagina och anus orsakad av HPV- typerna i vaccinet. • genitala vårtor (condyloma acuminata) orsakade av specifika HPV-typer. Se avsnitt 4.4 och 5.1 för viktig information om data som stöder dessa indikationer. Gardasil 9 bör användas i enlighet med officiella rekommendationer.", "language": "sv", "source": "canonical", "status": "CANONICAL_READY" }, "canonicalFacts": { "source": "canonical", "status": "CANONICAL_READY", "readyCount": 4, "blockedCount": 0, "rows": [ { "factType": "atc_code", "value": "J07BM03", "language": "sv", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "ema:eu-epar-product-information:gardasil-9", "sourceUrl": "https://www.ema.europa.eu/sv/documents/product-information/gardasil-9-epar-product-information_sv.pdf", "contentHash": "ac81b99b6dcf30bce58615ec8224ce38221b238be4ba19b79b0e59613cd7fb24", "citationTarget": "section:5.1", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "revision:29", "observedVersionIdentifier": "revision:29", "currentnessObservedAt": "2026-09-01T12:04:23.944+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "authorised_indication", "value": "Gardasil 9 är indicerat för aktiv immunisering av individer från 9 års ålder mot följande HPV- sjukdomar: • premaligna lesioner och cancer som påverkar cervix, vulva, vagina och anus orsakad av HPV- typerna i vaccinet. • genitala vårtor (condyloma acuminata) orsakade av specifika HPV-typer. Se avsnitt 4.4 och 5.1 för viktig information om data som stöder dessa indikationer. Gardasil 9 bör användas i enlighet med officiella rekommendationer.", "language": "sv", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "ema:eu-epar-product-information:gardasil-9", "sourceUrl": "https://www.ema.europa.eu/sv/documents/product-information/gardasil-9-epar-product-information_sv.pdf", "contentHash": "ac81b99b6dcf30bce58615ec8224ce38221b238be4ba19b79b0e59613cd7fb24", "citationTarget": "section:4.1", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "revision:29", "observedVersionIdentifier": "revision:29", "currentnessObservedAt": "2026-09-01T12:04:23.944+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "marketing_authorisation_holder", "value": "Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem Nederländerna", "language": "sv", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "ema:eu-epar-product-information:gardasil-9", "sourceUrl": "https://www.ema.europa.eu/sv/documents/product-information/gardasil-9-epar-product-information_sv.pdf", "contentHash": "ac81b99b6dcf30bce58615ec8224ce38221b238be4ba19b79b0e59613cd7fb24", "citationTarget": "section:7", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "revision:29", "observedVersionIdentifier": "revision:29", "currentnessObservedAt": "2026-09-01T12:04:23.944+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "pharmaceutical_form", "value": "Injektionsvätska, suspension. Klar vätska med en vit fällning.", "language": "sv", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "ema:eu-epar-product-information:gardasil-9", "sourceUrl": "https://www.ema.europa.eu/sv/documents/product-information/gardasil-9-epar-product-information_sv.pdf", "contentHash": "ac81b99b6dcf30bce58615ec8224ce38221b238be4ba19b79b0e59613cd7fb24", "citationTarget": "section:3", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "revision:29", "observedVersionIdentifier": "revision:29", "currentnessObservedAt": "2026-09-01T12:04:23.944+00:00", "sourceVerificationStatus": "unverified" } ] }, "documents": { "source": "canonical", "status": "CANONICAL_READY", "canonical": [ { "sourceKey": "ema:gardasil-9-produktinformation", "name": "EMA – Gardasil 9, produktinformation (EPAR)", "publisher": "European Medicines Agency", "url": "https://www.ema.europa.eu/sv/documents/product-information/gardasil-9-epar-product-information_sv.pdf", "retrievedAt": "2026-09-01T06:50:55.366193+00:00", "contentHash": "ac81b99b6dcf30bce58615ec8224ce38221b238be4ba19b79b0e59613cd7fb24", "sourceVerificationStatus": "unverified", "citationTargets": [ "section:2", "section:6.1" ] } ], "legacyCompatibility": [ { "label": "EMA EPAR – Gardasil 9", "url": "https://www.ema.europa.eu/en/documents/product-information/gardasil-9-epar-product-information_en.pdf" }, { "label": "FASS – Gardasil 9", "url": "https://www.fass.se/health/product/20140314000038/smpc" }, { "label": "FDA – Gardasil 9 Package Insert", "url": "https://www.fda.gov/media/90064/download" } ] }, "fieldMatrix": [ { "field": "identity", "layer": "identity", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "summary", "layer": "editorial", "source": "editorial", "status": "EDITORIAL_ONLY", "blocker": null }, { "field": "facts", "layer": "structured-fact", "source": "legacy-compatibility", "status": "LEGACY_COMPATIBILITY", "blocker": "Kvarvarande legacy-rader saknar ännu en kanonisk faktarad bunden till SourceVersion + CitationTarget. De behåller sin egen fältkälla och promotas inte." }, { "field": "canonicalFacts", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "regulatoryIndication", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "documents", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "programme", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "publication", "layer": "publication-policy", "source": "editorial", "status": "EDITORIAL_ONLY", "blocker": null } ] } }, { "id": "product:helcells-dtp", "key": "helcells-dtp", "name": "Helcellsvaccin mot kikhosta (DPT, historisk produkttyp)", "conceptKey": "dtp", "conceptName": "Difteri-, stelkramps- och kikhostevaccin (DTP)", "atcCode": null, "authorisationStatus": "historisk", "identitySource": "canonical_vaccine_product", "url": null, "canonicalUrl": null, "projection": { "note": "Fälten nedan är presentation, inte kanonisk identitet. Varje fältfamilj bär sin egen källa och readiness-status (RUN 11.5).", "summary": { "value": null, "source": "unavailable", "status": "BLOCKED_SEMANTIC_MODEL" }, "programme": { "source": "unavailable", "status": "BLOCKED_SEMANTIC_MODEL", "productLevelStatus": null, "productLevelStatusLabel": null, "currentness": null, "note": null, "currentCategories": [], "futureCategories": [], "productLevelEvidence": null }, "regulatoryIndication": { "value": null, "language": null, "source": "unavailable", "status": "NOT_APPLICABLE" }, "canonicalFacts": { "source": "unavailable", "status": "BLOCKED_SOURCE_VERSION", "readyCount": 0, "blockedCount": 0, "rows": [] }, "documents": { "source": "legacy-compatibility", "status": "BLOCKED_SOURCE_VERSION", "canonical": [], "legacyCompatibility": [] }, "fieldMatrix": [] } }, { "id": "product:infanrix-hexa", "key": "infanrix-hexa", "name": "Infanrix hexa", "conceptKey": "dtp", "conceptName": "Difteri-, stelkramps- och kikhostevaccin (DTP)", "atcCode": null, "authorisationStatus": "godkand", "identitySource": "canonical_vaccine_product", "url": null, "canonicalUrl": null, "projection": { "note": "Fälten nedan är presentation, inte kanonisk identitet. Varje fältfamilj bär sin egen källa och readiness-status (RUN 11.5).", "summary": { "value": null, "source": "unavailable", "status": "BLOCKED_SEMANTIC_MODEL" }, "programme": { "source": "unavailable", "status": "BLOCKED_SEMANTIC_MODEL", "productLevelStatus": null, "productLevelStatusLabel": null, "currentness": null, "note": null, "currentCategories": [], "futureCategories": [], "productLevelEvidence": null }, "regulatoryIndication": { "value": null, "language": null, "source": "unavailable", "status": "NOT_APPLICABLE" }, "canonicalFacts": { "source": "unavailable", "status": "BLOCKED_SOURCE_VERSION", "readyCount": 0, "blockedCount": 0, "rows": [] }, "documents": { "source": "legacy-compatibility", "status": "BLOCKED_SOURCE_VERSION", "canonical": [], "legacyCompatibility": [] }, "fieldMatrix": [] } }, { "id": "product:m-m-rvaxpro", "key": "m-m-rvaxpro", "name": "M-M-RVAXPRO", "conceptKey": "mpr", "conceptName": "MPR-vaccin (mässling, påssjuka, röda hund)", "atcCode": null, "authorisationStatus": null, "identitySource": "canonical_vaccine_product", "url": "https://antivaxxare.se/vacciner/m-m-rvaxpro", "canonicalUrl": "https://antivaxxare.se/vacciner/m-m-rvaxpro", "projection": { "note": "Fälten nedan är presentation, inte kanonisk identitet. Varje fältfamilj bär sin egen källa och readiness-status (RUN 11.5).", "summary": { "value": "Levande försvagat kombinationsvaccin mot mässling, påssjuka och röda hund.", "source": "editorial", "status": "EDITORIAL_ONLY" }, "programme": { "source": "canonical", "status": "CANONICAL_READY", "productLevelStatus": "CATEGORY_INCLUDED_PRODUCT_NOT_ESTABLISHED", "productLevelStatusLabel": "Ingår i programkategori — produktnivå ej fastställd", "currentness": "currentness-verified", "note": "Att begreppet ingår i programmet är inte ett belägg för att just denna handelsprodukt används. Vi har ingen aktuell officiell källa på produktnivå. Uppgiften redovisas som ej fastställd — inte som att produkten inte används.", "currentCategories": [ { "categoryKey": "mpr", "label": "Mässling, påssjuka, röda hund (MPR)", "inclusion": "included", "programVersion": "se-barn-2026", "validFrom": "2026-01-01", "schedule": [ { "dosePosition": 1, "ageGroup": "18 månader", "gradeBased": false }, { "dosePosition": 2, "ageGroup": "Årskurs 1–2", "gradeBased": true } ], "sourceKey": "fhm-barnvaccinationsprogram-oversikt", "sourceUrl": "https://www.folkhalsomyndigheten.se/vara-amnesomraden/vaccinationer/nationella-vaccinationsprogram/barnvaccinationsprogram/", "contentHash": "cd28f32b64c44642ae7db48259abe6c4160df042cfca6e84f6400f52c155ec10", "citationTarget": "Schematabell, rad \"Mässling, påssjuka, röda hund\"", "currentness": "currentness-verified" } ], "futureCategories": [], "productLevelEvidence": null }, "regulatoryIndication": { "value": "M-M-RvaxPro är indicerat för samtidig vaccinering mot mässling, påssjuka och röda hund av personer från 12 månaders ålder (se avsnitt 4.2). M-M-RvaxPro kan under särskilda omständigheter adminstreras till barn från 9 månaders ålder (se avsnitt 4.2, 4.4 och 5.1). För användning vid mässlingutbrott, vid vaccination efter exponering eller till tidigare ovaccinerade individer äldre än 9 månader som är i kontakt med mottagliga gravida kvinnor, samt till personer som kan antas vara känsliga för påssjuka och röda hund (se avsnitt 5.1). M-M-RvaxPro ska användas i enlighet med officiella rekommendationer.", "language": "sv", "source": "canonical", "status": "CANONICAL_READY" }, "canonicalFacts": { "source": "canonical", "status": "CANONICAL_READY", "readyCount": 4, "blockedCount": 0, "rows": [ { "factType": "atc_code", "value": "J07BD52", "language": "sv", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "smpc-sv:m-m-rvaxpro", "sourceUrl": "https://fass.se/health/product/20040916001344/smpc", "contentHash": "8e99b489a9a39b938afdf4e9ddd39c641982d2d17fd7db2690cc58512cdb0e71", "citationTarget": "section:5.1", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "smpc-revision-date:30 oktober 2025", "observedVersionIdentifier": "smpc-revision-date:30 oktober 2025", "currentnessObservedAt": "2026-09-01T12:04:29.928+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "authorised_indication", "value": "M-M-RvaxPro är indicerat för samtidig vaccinering mot mässling, påssjuka och röda hund av personer från 12 månaders ålder (se avsnitt 4.2). M-M-RvaxPro kan under särskilda omständigheter adminstreras till barn från 9 månaders ålder (se avsnitt 4.2, 4.4 och 5.1). För användning vid mässlingutbrott, vid vaccination efter exponering eller till tidigare ovaccinerade individer äldre än 9 månader som är i kontakt med mottagliga gravida kvinnor, samt till personer som kan antas vara känsliga för påssjuka och röda hund (se avsnitt 5.1). M-M-RvaxPro ska användas i enlighet med officiella rekommendationer.", "language": "sv", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "smpc-sv:m-m-rvaxpro", "sourceUrl": "https://fass.se/health/product/20040916001344/smpc", "contentHash": "8e99b489a9a39b938afdf4e9ddd39c641982d2d17fd7db2690cc58512cdb0e71", "citationTarget": "section:4.1", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "smpc-revision-date:30 oktober 2025", "observedVersionIdentifier": "smpc-revision-date:30 oktober 2025", "currentnessObservedAt": "2026-09-01T12:04:29.928+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "marketing_authorisation_holder", "value": "Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem Nederländerna", "language": "sv", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "smpc-sv:m-m-rvaxpro", "sourceUrl": "https://fass.se/health/product/20040916001344/smpc", "contentHash": "8e99b489a9a39b938afdf4e9ddd39c641982d2d17fd7db2690cc58512cdb0e71", "citationTarget": "section:7", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "smpc-revision-date:30 oktober 2025", "observedVersionIdentifier": "smpc-revision-date:30 oktober 2025", "currentnessObservedAt": "2026-09-01T12:04:29.928+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "pharmaceutical_form", "value": "Pulver och vätska till injektionsvätska, suspension (pulver till injektionsvätska). Före beredning är pulvret en ljusgul kompakt kristallin kaka och spädningsvätskan är klar och färglös.", "language": "sv", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "smpc-sv:m-m-rvaxpro", "sourceUrl": "https://fass.se/health/product/20040916001344/smpc", "contentHash": "8e99b489a9a39b938afdf4e9ddd39c641982d2d17fd7db2690cc58512cdb0e71", "citationTarget": "section:3", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "smpc-revision-date:30 oktober 2025", "observedVersionIdentifier": "smpc-revision-date:30 oktober 2025", "currentnessObservedAt": "2026-09-01T12:04:29.928+00:00", "sourceVerificationStatus": "unverified" } ] }, "documents": { "source": "canonical", "status": "CANONICAL_READY", "canonical": [ { "sourceKey": "fass:m-m-rvaxpro-produktinformation", "name": "FASS – M-M-RVAXPRO, produktresumé", "publisher": "FASS/Läkemedelsverket", "url": "https://fass.se/health/product/20040916001344/smpc", "retrievedAt": "2026-09-01T06:07:54.0752+00:00", "contentHash": "61cefed208cee921a03478d381454327c14d97b97bda2ccbc1d718e5ddcd2821", "sourceVerificationStatus": "unverified", "citationTargets": [ "Avsnitt 2", "Avsnitt 6.1" ] } ], "legacyCompatibility": [ { "label": "FASS – M-M-RVAXPRO, produktresumé", "url": "https://fass.se/health/product/20040916001344/smpc" } ] }, "fieldMatrix": [ { "field": "identity", "layer": "identity", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "summary", "layer": "editorial", "source": "editorial", "status": "EDITORIAL_ONLY", "blocker": null }, { "field": "facts", "layer": "structured-fact", "source": "legacy-compatibility", "status": "LEGACY_COMPATIBILITY", "blocker": "Kvarvarande legacy-rader saknar ännu en kanonisk faktarad bunden till SourceVersion + CitationTarget. De behåller sin egen fältkälla och promotas inte." }, { "field": "canonicalFacts", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "regulatoryIndication", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "documents", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "programme", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "publication", "layer": "publication-policy", "source": "editorial", "status": "EDITORIAL_ONLY", "blocker": null } ] } }, { "id": "product:priorix", "key": "priorix", "name": "Priorix", "conceptKey": "mpr", "conceptName": "MPR-vaccin (mässling, påssjuka, röda hund)", "atcCode": null, "authorisationStatus": null, "identitySource": "canonical_vaccine_product", "url": "https://antivaxxare.se/vacciner/priorix", "canonicalUrl": "https://antivaxxare.se/vacciner/priorix", "projection": { "note": "Fälten nedan är presentation, inte kanonisk identitet. Varje fältfamilj bär sin egen källa och readiness-status (RUN 11.5).", "summary": { "value": "Levande försvagat kombinationsvaccin mot mässling, påssjuka och röda hund med andra vaccinstammar än M-M-RVAXPRO.", "source": "editorial", "status": "EDITORIAL_ONLY" }, "programme": { "source": "canonical", "status": "CANONICAL_READY", "productLevelStatus": "CATEGORY_INCLUDED_PRODUCT_NOT_ESTABLISHED", "productLevelStatusLabel": "Ingår i programkategori — produktnivå ej fastställd", "currentness": "currentness-verified", "note": "Att begreppet ingår i programmet är inte ett belägg för att just denna handelsprodukt används. Vi har ingen aktuell officiell källa på produktnivå. Uppgiften redovisas som ej fastställd — inte som att produkten inte används.", "currentCategories": [ { "categoryKey": "mpr", "label": "Mässling, påssjuka, röda hund (MPR)", "inclusion": "included", "programVersion": "se-barn-2026", "validFrom": "2026-01-01", "schedule": [ { "dosePosition": 1, "ageGroup": "18 månader", "gradeBased": false }, { "dosePosition": 2, "ageGroup": "Årskurs 1–2", "gradeBased": true } ], "sourceKey": "fhm-barnvaccinationsprogram-oversikt", "sourceUrl": "https://www.folkhalsomyndigheten.se/vara-amnesomraden/vaccinationer/nationella-vaccinationsprogram/barnvaccinationsprogram/", "contentHash": "cd28f32b64c44642ae7db48259abe6c4160df042cfca6e84f6400f52c155ec10", "citationTarget": "Schematabell, rad \"Mässling, påssjuka, röda hund\"", "currentness": "currentness-verified" } ], "futureCategories": [], "productLevelEvidence": null }, "regulatoryIndication": { "value": "Priorix är indicerat för aktiv immunisering av barn från 9 månaders ålder eller äldre, ungdomar och vuxna mot mässling, påssjuka och röda hund. För användning till barn mellan 9 och 12 månaders ålder, se avsnitt 4.2, 4.4 och 5.1.", "language": "sv", "source": "canonical", "status": "CANONICAL_READY" }, "canonicalFacts": { "source": "canonical", "status": "CANONICAL_READY", "readyCount": 4, "blockedCount": 0, "rows": [ { "factType": "atc_code", "value": "J07BD52", "language": "sv", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "smpc-sv:priorix", "sourceUrl": "https://fass.se/health/product/19980717000112/smpc", "contentHash": "a62d9a83cf041cebf1686ee8ff524b4ddccd2a9b95e273eb5ee38f7734f2b302", "citationTarget": "section:5.1", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "smpc-revision-date:2026-05-05", "observedVersionIdentifier": "smpc-revision-date:2026-05-05", "currentnessObservedAt": "2026-09-01T12:04:31.493+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "authorised_indication", "value": "Priorix är indicerat för aktiv immunisering av barn från 9 månaders ålder eller äldre, ungdomar och vuxna mot mässling, påssjuka och röda hund. För användning till barn mellan 9 och 12 månaders ålder, se avsnitt 4.2, 4.4 och 5.1.", "language": "sv", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "smpc-sv:priorix", "sourceUrl": "https://fass.se/health/product/19980717000112/smpc", "contentHash": "a62d9a83cf041cebf1686ee8ff524b4ddccd2a9b95e273eb5ee38f7734f2b302", "citationTarget": "section:4.1", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "smpc-revision-date:2026-05-05", "observedVersionIdentifier": "smpc-revision-date:2026-05-05", "currentnessObservedAt": "2026-09-01T12:04:31.493+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "marketing_authorisation_holder", "value": "GlaxoSmithKline AB Box 516 169 29 Solna", "language": "sv", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "smpc-sv:priorix", "sourceUrl": "https://fass.se/health/product/19980717000112/smpc", "contentHash": "a62d9a83cf041cebf1686ee8ff524b4ddccd2a9b95e273eb5ee38f7734f2b302", "citationTarget": "section:7", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "smpc-revision-date:2026-05-05", "observedVersionIdentifier": "smpc-revision-date:2026-05-05", "currentnessObservedAt": "2026-09-01T12:04:31.493+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "pharmaceutical_form", "value": "Pulver och vätska till injektionsvätska, lösning i förfylld spruta. Före beredning är pulvret en vitaktig till svagt rosafärgad kaka, varav en del kan vara gulaktig till svagt orange. Spädningsvätskan (vatten för injektionsvätskor) är en klar och färglös vätska.", "language": "sv", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "smpc-sv:priorix", "sourceUrl": "https://fass.se/health/product/19980717000112/smpc", "contentHash": "a62d9a83cf041cebf1686ee8ff524b4ddccd2a9b95e273eb5ee38f7734f2b302", "citationTarget": "section:3", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "smpc-revision-date:2026-05-05", "observedVersionIdentifier": "smpc-revision-date:2026-05-05", "currentnessObservedAt": "2026-09-01T12:04:31.493+00:00", "sourceVerificationStatus": "unverified" } ] }, "documents": { "source": "canonical", "status": "CANONICAL_READY", "canonical": [ { "sourceKey": "fass:priorix-produktinformation", "name": "FASS – Priorix, produktresumé", "publisher": "FASS/Läkemedelsverket", "url": "https://fass.se/health/product/19980717000112/smpc", "retrievedAt": "2026-09-01T06:07:54.83428+00:00", "contentHash": "3ed7838861e5fe7c1572e9660de7a72536bb0e2df922ab07d4d49fe1ab1031bf", "sourceVerificationStatus": "unverified", "citationTargets": [ "Avsnitt 2", "Avsnitt 2 och 6.1", "Avsnitt 6.1" ] } ], "legacyCompatibility": [ { "label": "FASS – Priorix, produktresumé", "url": "https://fass.se/health/product/19980717000112/smpc" } ] }, "fieldMatrix": [ { "field": "identity", "layer": "identity", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "summary", "layer": "editorial", "source": "editorial", "status": "EDITORIAL_ONLY", "blocker": null }, { "field": "facts", "layer": "structured-fact", "source": "legacy-compatibility", "status": "LEGACY_COMPATIBILITY", "blocker": "Kvarvarande legacy-rader saknar ännu en kanonisk faktarad bunden till SourceVersion + CitationTarget. De behåller sin egen fältkälla och promotas inte." }, { "field": "canonicalFacts", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "regulatoryIndication", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "documents", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "programme", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "publication", "layer": "publication-policy", "source": "editorial", "status": "EDITORIAL_ONLY", "blocker": null } ] } }, { "id": "product:proquad", "key": "proquad", "name": "ProQuad", "conceptKey": "mpr", "conceptName": "MPR-vaccin (mässling, påssjuka, röda hund)", "atcCode": null, "authorisationStatus": null, "identitySource": "canonical_vaccine_product", "url": "https://antivaxxare.se/vacciner/proquad", "canonicalUrl": "https://antivaxxare.se/vacciner/proquad", "projection": { "note": "Fälten nedan är presentation, inte kanonisk identitet. Varje fältfamilj bär sin egen källa och readiness-status (RUN 11.5).", "summary": { "value": "Kombinationsvaccin mot mässling, påssjuka, röda hund och vattkoppor (MMRV). Produkten är relevant för den svenska programfrågan eftersom valet mellan MMRV och separata injektioner har en dokumenterad säkerhetsskillnad vid dos 1 i småbarnsåldern.", "source": "editorial", "status": "EDITORIAL_ONLY" }, "programme": { "source": "canonical", "status": "CANONICAL_READY", "productLevelStatus": "CATEGORY_INCLUDED_PRODUCT_NOT_ESTABLISHED", "productLevelStatusLabel": "Ingår i programkategori — produktnivå ej fastställd", "currentness": "currentness-verified", "note": "Att begreppet ingår i programmet är inte ett belägg för att just denna handelsprodukt används. Vi har ingen aktuell officiell källa på produktnivå. Uppgiften redovisas som ej fastställd — inte som att produkten inte används. Produkten berör dessutom vattkoppor, som är en beslutad framtida programkategori från januari 2027 — det säger ingenting om framtida upphandling.", "currentCategories": [ { "categoryKey": "mpr", "label": "Mässling, påssjuka, röda hund (MPR)", "inclusion": "included", "programVersion": "se-barn-2026", "validFrom": "2026-01-01", "schedule": [ { "dosePosition": 1, "ageGroup": "18 månader", "gradeBased": false }, { "dosePosition": 2, "ageGroup": "Årskurs 1–2", "gradeBased": true } ], "sourceKey": "fhm-barnvaccinationsprogram-oversikt", "sourceUrl": "https://www.folkhalsomyndigheten.se/vara-amnesomraden/vaccinationer/nationella-vaccinationsprogram/barnvaccinationsprogram/", "contentHash": "cd28f32b64c44642ae7db48259abe6c4160df042cfca6e84f6400f52c155ec10", "citationTarget": "Schematabell, rad \"Mässling, påssjuka, röda hund\"", "currentness": "currentness-verified" } ], "futureCategories": [ { "categoryKey": "varicella", "label": "Vattkoppor (varicella)", "inclusion": "future-scheduled", "programVersion": "se-barn-2027-vattkoppor", "validFrom": "2027-01-01", "schedule": [ { "dosePosition": 1, "ageGroup": "18 månader", "gradeBased": false }, { "dosePosition": 2, "ageGroup": "Årskurs 1–2", "gradeBased": true } ], "sourceKey": "fhm-vattkoppor-vardnadshavare", "sourceUrl": "https://www.folkhalsomyndigheten.se/vara-amnesomraden/vaccinationer/vaccinationer-a-o/vaccination-mot-vattkoppor/information-till-vardnadshavare-om-vaccination-mot-vattkoppor-for-barn/", "contentHash": "a6b95082ca0488236f375d837248345e8a141dc628c4ade409631b926befc2f2", "citationTarget": "Avsnitt om när vaccinationen ges", "currentness": "currentness-verified" } ], "productLevelEvidence": null }, "regulatoryIndication": { "value": "ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age. ProQuad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles; see sections 4.2, 4.4, and 5.1). 2", "language": "en", "source": "canonical", "status": "CANONICAL_READY" }, "canonicalFacts": { "source": "canonical", "status": "CANONICAL_READY", "readyCount": 4, "blockedCount": 0, "rows": [ { "factType": "atc_code", "value": "J07BD54", "language": "en", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "ema:eu-epar-product-information:proquad", "sourceUrl": "https://www.ema.europa.eu/en/documents/product-information/proquad-epar-product-information_en.pdf", "contentHash": "10f5a1e20845cc2273c111fca146c4950a4ba676fc814ddf4efcc5e150ea48b9", "citationTarget": "section:5.1", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "revision:36", "observedVersionIdentifier": "revision:36", "currentnessObservedAt": "2026-09-01T12:04:25.575+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "authorised_indication", "value": "ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age. ProQuad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles; see sections 4.2, 4.4, and 5.1). 2", "language": "en", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "ema:eu-epar-product-information:proquad", "sourceUrl": "https://www.ema.europa.eu/en/documents/product-information/proquad-epar-product-information_en.pdf", "contentHash": "10f5a1e20845cc2273c111fca146c4950a4ba676fc814ddf4efcc5e150ea48b9", "citationTarget": "section:4.1", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "revision:36", "observedVersionIdentifier": "revision:36", "currentnessObservedAt": "2026-09-01T12:04:25.575+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "marketing_authorisation_holder", "value": "Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem The Netherlands", "language": "en", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "ema:eu-epar-product-information:proquad", "sourceUrl": "https://www.ema.europa.eu/en/documents/product-information/proquad-epar-product-information_en.pdf", "contentHash": "10f5a1e20845cc2273c111fca146c4950a4ba676fc814ddf4efcc5e150ea48b9", "citationTarget": "section:7", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "revision:36", "observedVersionIdentifier": "revision:36", "currentnessObservedAt": "2026-09-01T12:04:25.575+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "pharmaceutical_form", "value": "Powder and solvent for suspension for injection (powder for injection). Before reconstitution, the powder is a white to pale yellow compact crystalline cake and the solvent is a clear colourless liquid.", "language": "en", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "ema:eu-epar-product-information:proquad", "sourceUrl": "https://www.ema.europa.eu/en/documents/product-information/proquad-epar-product-information_en.pdf", "contentHash": "10f5a1e20845cc2273c111fca146c4950a4ba676fc814ddf4efcc5e150ea48b9", "citationTarget": "section:3", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "revision:36", "observedVersionIdentifier": "revision:36", "currentnessObservedAt": "2026-09-01T12:04:25.575+00:00", "sourceVerificationStatus": "unverified" } ] }, "documents": { "source": "canonical", "status": "CANONICAL_READY", "canonical": [ { "sourceKey": "ema:proquad-produktinformation", "name": "EMA – ProQuad, produktinformation (EPAR)", "publisher": "European Medicines Agency", "url": "https://www.ema.europa.eu/en/documents/product-information/proquad-epar-product-information_en.pdf", "retrievedAt": "2026-09-01T06:50:56.681487+00:00", "contentHash": "10f5a1e20845cc2273c111fca146c4950a4ba676fc814ddf4efcc5e150ea48b9", "sourceVerificationStatus": "unverified", "citationTargets": [ "section:2", "section:6.1" ] } ], "legacyCompatibility": [ { "label": "EMA EPAR – ProQuad, produktinformation", "url": "https://www.ema.europa.eu/en/documents/product-information/proquad-epar-product-information_sv.pdf" }, { "label": "Adda – upphandling av vattkoppsvaccin", "url": "https://www.adda.se/upphandling-och-ramavtal/planerade-och-pagaende-upphandlingar/vaccin-enligt-det-nationella-barnvaccinationsprogrammet-2025---vattkoppor/" } ] }, "fieldMatrix": [ { "field": "identity", "layer": "identity", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "summary", "layer": "editorial", "source": "editorial", "status": "EDITORIAL_ONLY", "blocker": null }, { "field": "facts", "layer": "structured-fact", "source": "legacy-compatibility", "status": "LEGACY_COMPATIBILITY", "blocker": "Kvarvarande legacy-rader saknar ännu en kanonisk faktarad bunden till SourceVersion + CitationTarget. De behåller sin egen fältkälla och promotas inte." }, { "field": "canonicalFacts", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "regulatoryIndication", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "documents", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "programme", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "publication", "layer": "publication-policy", "source": "editorial", "status": "EDITORIAL_ONLY", "blocker": null } ] } }, { "id": "product:rotarix", "key": "rotarix", "name": "Rotarix", "conceptKey": "rotavirus", "conceptName": "Rotavirusvaccin", "atcCode": null, "authorisationStatus": null, "identitySource": "canonical_vaccine_product", "url": "https://antivaxxare.se/vacciner/rotarix", "canonicalUrl": "https://antivaxxare.se/vacciner/rotarix", "projection": { "note": "Fälten nedan är presentation, inte kanonisk identitet. Varje fältfamilj bär sin egen källa och readiness-status (RUN 11.5).", "summary": { "value": "Levande försvagat rotavirusvaccin som ges som droppar i munnen.", "source": "editorial", "status": "EDITORIAL_ONLY" }, "programme": { "source": "canonical", "status": "BLOCKED_CURRENTNESS", "productLevelStatus": "PROCUREMENT_DEPENDENT_PRODUCT_NOT_ESTABLISHED", "productLevelStatusLabel": "Ingår i programkategori — vilket märke som används avgörs av upphandling", "currentness": "currentness-unknown", "note": "Att källan namnger två godkända rotavirusvacciner är inte ett belägg för att båda används i programmet. Källan säger uttryckligen att märket avgörs av upphandling, och den upphandlingskällan har vi inte.", "currentCategories": [ { "categoryKey": "rotavirus", "label": "Rotavirus", "inclusion": "included", "programVersion": "se-barn-2026", "validFrom": "2026-01-01", "schedule": [ { "dosePosition": 1, "ageGroup": "6 veckor", "gradeBased": false }, { "dosePosition": 2, "ageGroup": "3 månader", "gradeBased": false }, { "dosePosition": 3, "ageGroup": "5 månader", "gradeBased": false } ], "sourceKey": "fhm-barnvaccinationsprogram-oversikt", "sourceUrl": "https://www.folkhalsomyndigheten.se/vara-amnesomraden/vaccinationer/nationella-vaccinationsprogram/barnvaccinationsprogram/", "contentHash": "cd28f32b64c44642ae7db48259abe6c4160df042cfca6e84f6400f52c155ec10", "citationTarget": "Schematabell, rad \"Rotavirus\"", "currentness": "currentness-verified" } ], "futureCategories": [], "productLevelEvidence": null }, "regulatoryIndication": { "value": "Rotarix is indicated for the active immunisation of infants aged 6 to 24 weeks for prevention of gastro- enteritis due to rotavirus infection (see sections 4.2, 4.4 and 5.1). The use of Rotarix should be based on official recommendations.", "language": "en", "source": "canonical", "status": "CANONICAL_READY" }, "canonicalFacts": { "source": "canonical", "status": "CANONICAL_READY", "readyCount": 4, "blockedCount": 0, "rows": [ { "factType": "atc_code", "value": "J07BH01", "language": "en", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "ema:eu-epar-product-information:rotarix", "sourceUrl": "https://www.ema.europa.eu/en/documents/product-information/rotarix-epar-product-information_en.pdf", "contentHash": "f23b92155af2a799873ddb039ec57778f448d925c2393447f46e97faf79dd9d4", "citationTarget": "section:5.1", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "revision:48", "observedVersionIdentifier": "revision:48", "currentnessObservedAt": "2026-09-01T12:04:26.926+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "authorised_indication", "value": "Rotarix is indicated for the active immunisation of infants aged 6 to 24 weeks for prevention of gastro- enteritis due to rotavirus infection (see sections 4.2, 4.4 and 5.1). The use of Rotarix should be based on official recommendations.", "language": "en", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "ema:eu-epar-product-information:rotarix", "sourceUrl": "https://www.ema.europa.eu/en/documents/product-information/rotarix-epar-product-information_en.pdf", "contentHash": "f23b92155af2a799873ddb039ec57778f448d925c2393447f46e97faf79dd9d4", "citationTarget": "section:4.1", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "revision:48", "observedVersionIdentifier": "revision:48", "currentnessObservedAt": "2026-09-01T12:04:26.926+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "marketing_authorisation_holder", "value": "GlaxoSmithKline Biologicals SA Rue de l'Institut 89 B-1330 Rixensart, Belgium", "language": "en", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "ema:eu-epar-product-information:rotarix", "sourceUrl": "https://www.ema.europa.eu/en/documents/product-information/rotarix-epar-product-information_en.pdf", "contentHash": "f23b92155af2a799873ddb039ec57778f448d925c2393447f46e97faf79dd9d4", "citationTarget": "section:7", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "revision:48", "observedVersionIdentifier": "revision:48", "currentnessObservedAt": "2026-09-01T12:04:26.926+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "pharmaceutical_form", "value": "Oral suspension. Rotarix is a clear and colourless liquid.", "language": "en", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "ema:eu-epar-product-information:rotarix", "sourceUrl": "https://www.ema.europa.eu/en/documents/product-information/rotarix-epar-product-information_en.pdf", "contentHash": "f23b92155af2a799873ddb039ec57778f448d925c2393447f46e97faf79dd9d4", "citationTarget": "section:3", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "revision:48", "observedVersionIdentifier": "revision:48", "currentnessObservedAt": "2026-09-01T12:04:26.926+00:00", "sourceVerificationStatus": "unverified" } ] }, "documents": { "source": "canonical", "status": "CANONICAL_READY", "canonical": [ { "sourceKey": "ema:eu-epar-product-information:rotarix", "name": "EMA – Rotarix, EPAR Product Information (Annex I, SmPC)", "publisher": "European Medicines Agency", "url": "https://www.ema.europa.eu/en/documents/product-information/rotarix-epar-product-information_en.pdf", "retrievedAt": "2026-09-01T11:12:34.999336+00:00", "contentHash": "f23b92155af2a799873ddb039ec57778f448d925c2393447f46e97faf79dd9d4", "sourceVerificationStatus": "unverified", "citationTargets": [ "section:2", "section:6.1" ] } ], "legacyCompatibility": [ { "label": "EMA EPAR – Rotarix", "url": "https://www.ema.europa.eu/en/documents/product-information/rotarix-epar-product-information_sv.pdf" }, { "label": "FASS – Rotarix", "url": "https://www.fass.se/health/product/20160913000086/smpc" }, { "label": "FDA – Rotarix Package Insert", "url": "https://www.fda.gov/media/75726/download" } ] }, "fieldMatrix": [ { "field": "identity", "layer": "identity", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "summary", "layer": "editorial", "source": "editorial", "status": "EDITORIAL_ONLY", "blocker": null }, { "field": "facts", "layer": "structured-fact", "source": "legacy-compatibility", "status": "LEGACY_COMPATIBILITY", "blocker": "Kvarvarande legacy-rader saknar ännu en kanonisk faktarad bunden till SourceVersion + CitationTarget. De behåller sin egen fältkälla och promotas inte." }, { "field": "canonicalFacts", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "regulatoryIndication", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "documents", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "programme", "layer": "structured-fact", "source": "canonical", "status": "BLOCKED_CURRENTNESS", "blocker": null }, { "field": "publication", "layer": "publication-policy", "source": "editorial", "status": "EDITORIAL_ONLY", "blocker": null } ] } }, { "id": "product:rotateq", "key": "rotateq", "name": "RotaTeq", "conceptKey": "rotavirus", "conceptName": "Rotavirusvaccin", "atcCode": null, "authorisationStatus": null, "identitySource": "canonical_vaccine_product", "url": "https://antivaxxare.se/vacciner/rotateq", "canonicalUrl": "https://antivaxxare.se/vacciner/rotateq", "projection": { "note": "Fälten nedan är presentation, inte kanonisk identitet. Varje fältfamilj bär sin egen källa och readiness-status (RUN 11.5).", "summary": { "value": "Levande, femvalent rotavirusvaccin som ges som droppar i munnen.", "source": "editorial", "status": "EDITORIAL_ONLY" }, "programme": { "source": "canonical", "status": "BLOCKED_CURRENTNESS", "productLevelStatus": "PROCUREMENT_DEPENDENT_PRODUCT_NOT_ESTABLISHED", "productLevelStatusLabel": "Ingår i programkategori — vilket märke som används avgörs av upphandling", "currentness": "currentness-unknown", "note": "Att källan namnger två godkända rotavirusvacciner är inte ett belägg för att båda används i programmet. Källan säger uttryckligen att märket avgörs av upphandling, och den upphandlingskällan har vi inte.", "currentCategories": [ { "categoryKey": "rotavirus", "label": "Rotavirus", "inclusion": "included", "programVersion": "se-barn-2026", "validFrom": "2026-01-01", "schedule": [ { "dosePosition": 1, "ageGroup": "6 veckor", "gradeBased": false }, { "dosePosition": 2, "ageGroup": "3 månader", "gradeBased": false }, { "dosePosition": 3, "ageGroup": "5 månader", "gradeBased": false } ], "sourceKey": "fhm-barnvaccinationsprogram-oversikt", "sourceUrl": "https://www.folkhalsomyndigheten.se/vara-amnesomraden/vaccinationer/nationella-vaccinationsprogram/barnvaccinationsprogram/", "contentHash": "cd28f32b64c44642ae7db48259abe6c4160df042cfca6e84f6400f52c155ec10", "citationTarget": "Schematabell, rad \"Rotavirus\"", "currentness": "currentness-verified" } ], "futureCategories": [], "productLevelEvidence": null }, "regulatoryIndication": { "value": "RotaTeq is indicated for the active immunisation of infants from the age of 6 weeks to 32 weeks for prevention of gastroenteritis due to rotavirus infection (see sections 4.2, 4.4 and 5.1). RotaTeq is to be used on the basis of official recommendations.", "language": "en", "source": "canonical", "status": "CANONICAL_READY" }, "canonicalFacts": { "source": "canonical", "status": "CANONICAL_READY", "readyCount": 4, "blockedCount": 0, "rows": [ { "factType": "atc_code", "value": "J07BH02", "language": "en", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "ema:eu-epar-product-information:rotateq", "sourceUrl": "https://www.ema.europa.eu/en/documents/product-information/rotateq-epar-product-information_en.pdf", "contentHash": "1bf679a506a5932e9a995a26e74853821492506bfaf86c692c3c8611fb958c00", "citationTarget": "section:5.1", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "revision:39", "observedVersionIdentifier": "revision:39", "currentnessObservedAt": "2026-09-01T12:04:28.103+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "authorised_indication", "value": "RotaTeq is indicated for the active immunisation of infants from the age of 6 weeks to 32 weeks for prevention of gastroenteritis due to rotavirus infection (see sections 4.2, 4.4 and 5.1). RotaTeq is to be used on the basis of official recommendations.", "language": "en", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "ema:eu-epar-product-information:rotateq", "sourceUrl": "https://www.ema.europa.eu/en/documents/product-information/rotateq-epar-product-information_en.pdf", "contentHash": "1bf679a506a5932e9a995a26e74853821492506bfaf86c692c3c8611fb958c00", "citationTarget": "section:4.1", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "revision:39", "observedVersionIdentifier": "revision:39", "currentnessObservedAt": "2026-09-01T12:04:28.103+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "marketing_authorisation_holder", "value": "Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands.", "language": "en", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "ema:eu-epar-product-information:rotateq", "sourceUrl": "https://www.ema.europa.eu/en/documents/product-information/rotateq-epar-product-information_en.pdf", "contentHash": "1bf679a506a5932e9a995a26e74853821492506bfaf86c692c3c8611fb958c00", "citationTarget": "section:7", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "revision:39", "observedVersionIdentifier": "revision:39", "currentnessObservedAt": "2026-09-01T12:04:28.103+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "pharmaceutical_form", "value": "Oral Solution Pale yellow clear liquid that may have a pink tint", "language": "en", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "ema:eu-epar-product-information:rotateq", "sourceUrl": "https://www.ema.europa.eu/en/documents/product-information/rotateq-epar-product-information_en.pdf", "contentHash": "1bf679a506a5932e9a995a26e74853821492506bfaf86c692c3c8611fb958c00", "citationTarget": "section:3", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "revision:39", "observedVersionIdentifier": "revision:39", "currentnessObservedAt": "2026-09-01T12:04:28.103+00:00", "sourceVerificationStatus": "unverified" } ] }, "documents": { "source": "canonical", "status": "CANONICAL_READY", "canonical": [ { "sourceKey": "ema:eu-epar-product-information:rotateq", "name": "EMA – RotaTeq, EPAR Product Information (Annex I, SmPC)", "publisher": "European Medicines Agency", "url": "https://www.ema.europa.eu/en/documents/product-information/rotateq-epar-product-information_en.pdf", "retrievedAt": "2026-09-01T11:12:36.015919+00:00", "contentHash": "1bf679a506a5932e9a995a26e74853821492506bfaf86c692c3c8611fb958c00", "sourceVerificationStatus": "unverified", "citationTargets": [ "section:2", "section:6.1" ] } ], "legacyCompatibility": [ { "label": "EMA EPAR – RotaTeq", "url": "https://www.ema.europa.eu/en/documents/product-information/rotateq-epar-product-information_sv.pdf" }, { "label": "FDA – RotaTeq Package Insert", "url": "https://www.fda.gov/media/75718/download" } ] }, "fieldMatrix": [ { "field": "identity", "layer": "identity", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "summary", "layer": "editorial", "source": "editorial", "status": "EDITORIAL_ONLY", "blocker": null }, { "field": "facts", "layer": "structured-fact", "source": "legacy-compatibility", "status": "LEGACY_COMPATIBILITY", "blocker": "Kvarvarande legacy-rader saknar ännu en kanonisk faktarad bunden till SourceVersion + CitationTarget. De behåller sin egen fältkälla och promotas inte." }, { "field": "canonicalFacts", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "regulatoryIndication", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "documents", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "programme", "layer": "structured-fact", "source": "canonical", "status": "BLOCKED_CURRENTNESS", "blocker": null }, { "field": "publication", "layer": "publication-policy", "source": "editorial", "status": "EDITORIAL_ONLY", "blocker": null } ] } }, { "id": "product:varilrix", "key": "varilrix", "name": "Varilrix", "conceptKey": "varicella", "conceptName": "Varicellavaccin", "atcCode": null, "authorisationStatus": null, "identitySource": "canonical_vaccine_product", "url": "https://antivaxxare.se/vacciner/varilrix", "canonicalUrl": "https://antivaxxare.se/vacciner/varilrix", "projection": { "note": "Fälten nedan är presentation, inte kanonisk identitet. Varje fältfamilj bär sin egen källa och readiness-status (RUN 11.5).", "summary": { "value": "Monovalent levande försvagat vattkoppsvaccin av Oka-stam. Produkten har en egen produktresumé; vilket preparat som upphandlas till det svenska programmet 2027 är inte fastställt i vårt underlag.", "source": "editorial", "status": "EDITORIAL_ONLY" }, "programme": { "source": "canonical", "status": "CANONICAL_READY", "productLevelStatus": "FUTURE_CATEGORY_PRODUCT_NOT_ESTABLISHED", "productLevelStatusLabel": "Framtida programstart — produktnivå ej fastställd", "currentness": "currentness-verified", "note": "Vattkoppor är en beslutad framtida programkategori från januari 2027. Ingen källa säger vilken produkt som kommer att upphandlas, och vi gissar inte.", "currentCategories": [], "futureCategories": [ { "categoryKey": "varicella", "label": "Vattkoppor (varicella)", "inclusion": "future-scheduled", "programVersion": "se-barn-2027-vattkoppor", "validFrom": "2027-01-01", "schedule": [ { "dosePosition": 1, "ageGroup": "18 månader", "gradeBased": false }, { "dosePosition": 2, "ageGroup": "Årskurs 1–2", "gradeBased": true } ], "sourceKey": "fhm-vattkoppor-vardnadshavare", "sourceUrl": "https://www.folkhalsomyndigheten.se/vara-amnesomraden/vaccinationer/vaccinationer-a-o/vaccination-mot-vattkoppor/information-till-vardnadshavare-om-vaccination-mot-vattkoppor-for-barn/", "contentHash": "a6b95082ca0488236f375d837248345e8a141dc628c4ade409631b926befc2f2", "citationTarget": "Avsnitt om när vaccinationen ges", "currentness": "currentness-verified" } ], "productLevelEvidence": null }, "regulatoryIndication": { "value": "Varilrix är avsett för aktiv immunisering mot varicella: hos friska individer från 9 till 11 månaders ålder (se avsnitt 5.1), under särskilda omständigheter, hos friska individer från 12 månaders ålder (se avsnitt 5.1), som profylax efter exponering om administrering sker till friska, mottagliga individer som exponerats för varicella, inom 72 timmar efter kontakt (se avsnitt 4.4 och 5.1), hos individer med hög risk att drabbas av allvarlig varicella (se avsnitt 4.3, 4.4 och 5.1). Användning av Varilrix ska följa officiella rekommendationer.", "language": "sv", "source": "canonical", "status": "CANONICAL_READY" }, "canonicalFacts": { "source": "canonical", "status": "CANONICAL_READY", "readyCount": 4, "blockedCount": 0, "rows": [ { "factType": "atc_code", "value": "J07BK01", "language": "sv", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "smpc-sv:varilrix", "sourceUrl": "https://fass.se/health/product/19941017000073/smpc", "contentHash": "dd932be2688a5bf7e0d4a9900e81832111a504dcf1f0436a51b1e21ce0ca07e6", "citationTarget": "section:5.1", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "smpc-revision-date:2026-05-05", "observedVersionIdentifier": "smpc-revision-date:2026-05-05", "currentnessObservedAt": "2026-09-01T12:04:32.974+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "authorised_indication", "value": "Varilrix är avsett för aktiv immunisering mot varicella: hos friska individer från 9 till 11 månaders ålder (se avsnitt 5.1), under särskilda omständigheter, hos friska individer från 12 månaders ålder (se avsnitt 5.1), som profylax efter exponering om administrering sker till friska, mottagliga individer som exponerats för varicella, inom 72 timmar efter kontakt (se avsnitt 4.4 och 5.1), hos individer med hög risk att drabbas av allvarlig varicella (se avsnitt 4.3, 4.4 och 5.1). Användning av Varilrix ska följa officiella rekommendationer.", "language": "sv", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "smpc-sv:varilrix", "sourceUrl": "https://fass.se/health/product/19941017000073/smpc", "contentHash": "dd932be2688a5bf7e0d4a9900e81832111a504dcf1f0436a51b1e21ce0ca07e6", "citationTarget": "section:4.1", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "smpc-revision-date:2026-05-05", "observedVersionIdentifier": "smpc-revision-date:2026-05-05", "currentnessObservedAt": "2026-09-01T12:04:32.974+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "marketing_authorisation_holder", "value": "GlaxoSmithKline AB Box 516 169 29 Solna", "language": "sv", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "smpc-sv:varilrix", "sourceUrl": "https://fass.se/health/product/19941017000073/smpc", "contentHash": "dd932be2688a5bf7e0d4a9900e81832111a504dcf1f0436a51b1e21ce0ca07e6", "citationTarget": "section:7", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "smpc-revision-date:2026-05-05", "observedVersionIdentifier": "smpc-revision-date:2026-05-05", "currentnessObservedAt": "2026-09-01T12:04:32.974+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "pharmaceutical_form", "value": "Pulver och vätska till injektionsvätska, lösning i förfylld spruta. Före beredning, svagt krämfärgad till gulaktig eller rosafärgad torrsubstans i injektionsflaska. Spädningsvätskan är klar och färglös.", "language": "sv", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "smpc-sv:varilrix", "sourceUrl": "https://fass.se/health/product/19941017000073/smpc", "contentHash": "dd932be2688a5bf7e0d4a9900e81832111a504dcf1f0436a51b1e21ce0ca07e6", "citationTarget": "section:3", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "smpc-revision-date:2026-05-05", "observedVersionIdentifier": "smpc-revision-date:2026-05-05", "currentnessObservedAt": "2026-09-01T12:04:32.974+00:00", "sourceVerificationStatus": "unverified" } ] }, "documents": { "source": "canonical", "status": "CANONICAL_READY", "canonical": [ { "sourceKey": "fass:varilrix-produktresume", "name": "FASS – Varilrix, produktresumé (SmPC)", "publisher": "FASS/Läkemedelsverket", "url": "https://fass.se/health/product/19941017000073/smpc", "retrievedAt": "2026-09-01T06:50:57.695299+00:00", "contentHash": "5b4a0c079f00e5d79f399746f1178361fed58df479ca7b463f25dd9288a23605", "sourceVerificationStatus": "unverified", "citationTargets": [ "section:2", "section:6.1" ] } ], "legacyCompatibility": [ { "label": "FASS – Varilrix, produktresumé", "url": "https://www.fass.se/health/product/19941017000073/smpc" }, { "label": "Adda – upphandling av vattkoppsvaccin", "url": "https://www.adda.se/upphandling-och-ramavtal/planerade-och-pagaende-upphandlingar/vaccin-enligt-det-nationella-barnvaccinationsprogrammet-2025---vattkoppor/" } ] }, "fieldMatrix": [ { "field": "identity", "layer": "identity", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "summary", "layer": "editorial", "source": "editorial", "status": "EDITORIAL_ONLY", "blocker": null }, { "field": "facts", "layer": "structured-fact", "source": "legacy-compatibility", "status": "LEGACY_COMPATIBILITY", "blocker": "Kvarvarande legacy-rader saknar ännu en kanonisk faktarad bunden till SourceVersion + CitationTarget. De behåller sin egen fältkälla och promotas inte." }, { "field": "canonicalFacts", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "regulatoryIndication", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "documents", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "programme", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "publication", "layer": "publication-policy", "source": "editorial", "status": "EDITORIAL_ONLY", "blocker": null } ] } }, { "id": "product:varivax", "key": "varivax", "name": "Varivax", "conceptKey": "varicella", "conceptName": "Varicellavaccin", "atcCode": null, "authorisationStatus": null, "identitySource": "canonical_vaccine_product", "url": "https://antivaxxare.se/vacciner/varivax", "canonicalUrl": "https://antivaxxare.se/vacciner/varivax", "projection": { "note": "Fälten nedan är presentation, inte kanonisk identitet. Varje fältfamilj bär sin egen källa och readiness-status (RUN 11.5).", "summary": { "value": "Monovalent levande försvagat vattkoppsvaccin av Oka/Merck-stam. Det är den stamlinje som användes i den placebokontrollerade prövningen från 1984, men försöksformuleringen är inte identisk med dagens produkt.", "source": "editorial", "status": "EDITORIAL_ONLY" }, "programme": { "source": "canonical", "status": "CANONICAL_READY", "productLevelStatus": "FUTURE_CATEGORY_PRODUCT_NOT_ESTABLISHED", "productLevelStatusLabel": "Framtida programstart — produktnivå ej fastställd", "currentness": "currentness-verified", "note": "Vattkoppor är en beslutad framtida programkategori från januari 2027. Ingen källa säger vilken produkt som kommer att upphandlas, och vi gissar inte.", "currentCategories": [], "futureCategories": [ { "categoryKey": "varicella", "label": "Vattkoppor (varicella)", "inclusion": "future-scheduled", "programVersion": "se-barn-2027-vattkoppor", "validFrom": "2027-01-01", "schedule": [ { "dosePosition": 1, "ageGroup": "18 månader", "gradeBased": false }, { "dosePosition": 2, "ageGroup": "Årskurs 1–2", "gradeBased": true } ], "sourceKey": "fhm-vattkoppor-vardnadshavare", "sourceUrl": "https://www.folkhalsomyndigheten.se/vara-amnesomraden/vaccinationer/vaccinationer-a-o/vaccination-mot-vattkoppor/information-till-vardnadshavare-om-vaccination-mot-vattkoppor-for-barn/", "contentHash": "a6b95082ca0488236f375d837248345e8a141dc628c4ade409631b926befc2f2", "citationTarget": "Avsnitt om när vaccinationen ges", "currentness": "currentness-verified" } ], "productLevelEvidence": null }, "regulatoryIndication": { "value": "Varivax är avsett för vaccinering mot vattkoppor hos individer från 12 månaders ålder (se avsnitt 4.2 och 5.1). Varivax kan administreras till spädbarn från 9 månaders ålder under särskilda omständigheter, som för att följa nationella vaccinationsprogram eller i utbrottssituationer (se avsnitt 4.2, 4.5 och 5.1). Varivax kan också administreras till mottagliga personer som har exponerats för vattkoppor. Vaccinering inom 3 dagar efter exponeringen kan förhindra en kliniskt märkbar infektion eller förändra infektionens förlopp. Dessutom finns begränsade data som indikerar att vaccination upp till 5 dagar efter exponering kan förändra infektionens förlopp (se avsnitt 5.1).", "language": "sv", "source": "canonical", "status": "CANONICAL_READY" }, "canonicalFacts": { "source": "canonical", "status": "CANONICAL_READY", "readyCount": 4, "blockedCount": 0, "rows": [ { "factType": "atc_code", "value": "J07BK01", "language": "sv", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "smpc-sv:varivax", "sourceUrl": "https://fass.se/health/product/20040607000762/smpc", "contentHash": "bdbd157fc0184d96705137d5c4fab323bf4aade3c9f42cb974395b9357a32b21", "citationTarget": "section:5.1", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "smpc-revision-date:2025-10-27", "observedVersionIdentifier": "smpc-revision-date:2025-10-27", "currentnessObservedAt": "2026-09-01T12:04:34.501+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "authorised_indication", "value": "Varivax är avsett för vaccinering mot vattkoppor hos individer från 12 månaders ålder (se avsnitt 4.2 och 5.1). Varivax kan administreras till spädbarn från 9 månaders ålder under särskilda omständigheter, som för att följa nationella vaccinationsprogram eller i utbrottssituationer (se avsnitt 4.2, 4.5 och 5.1). Varivax kan också administreras till mottagliga personer som har exponerats för vattkoppor. Vaccinering inom 3 dagar efter exponeringen kan förhindra en kliniskt märkbar infektion eller förändra infektionens förlopp. Dessutom finns begränsade data som indikerar att vaccination upp till 5 dagar efter exponering kan förändra infektionens förlopp (se avsnitt 5.1).", "language": "sv", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "smpc-sv:varivax", "sourceUrl": "https://fass.se/health/product/20040607000762/smpc", "contentHash": "bdbd157fc0184d96705137d5c4fab323bf4aade3c9f42cb974395b9357a32b21", "citationTarget": "section:4.1", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "smpc-revision-date:2025-10-27", "observedVersionIdentifier": "smpc-revision-date:2025-10-27", "currentnessObservedAt": "2026-09-01T12:04:34.501+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "marketing_authorisation_holder", "value": "Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem Nederländerna", "language": "sv", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "smpc-sv:varivax", "sourceUrl": "https://fass.se/health/product/20040607000762/smpc", "contentHash": "bdbd157fc0184d96705137d5c4fab323bf4aade3c9f42cb974395b9357a32b21", "citationTarget": "section:7", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "smpc-revision-date:2025-10-27", "observedVersionIdentifier": "smpc-revision-date:2025-10-27", "currentnessObservedAt": "2026-09-01T12:04:34.501+00:00", "sourceVerificationStatus": "unverified" }, { "factType": "pharmaceutical_form", "value": "Pulver och vätska till injektionsvätska, suspension. Vitt till benvitt pulver och klar, färglös vätskelösning.", "language": "sv", "unknownReason": null, "status": "CANONICAL_READY", "sourceKey": "smpc-sv:varivax", "sourceUrl": "https://fass.se/health/product/20040607000762/smpc", "contentHash": "bdbd157fc0184d96705137d5c4fab323bf4aade3c9f42cb974395b9357a32b21", "citationTarget": "section:3", "currentnessStatus": "currentness-verified", "expectedVersionIdentifier": "smpc-revision-date:2025-10-27", "observedVersionIdentifier": "smpc-revision-date:2025-10-27", "currentnessObservedAt": "2026-09-01T12:04:34.501+00:00", "sourceVerificationStatus": "unverified" } ] }, "documents": { "source": "canonical", "status": "CANONICAL_READY", "canonical": [ { "sourceKey": "fass:varivax-produktresume", "name": "FASS – Varivax, produktresumé (SmPC)", "publisher": "FASS/Läkemedelsverket", "url": "https://fass.se/health/product/20040607000762/smpc", "retrievedAt": "2026-09-01T06:50:58.530993+00:00", "contentHash": "16ddbfbb489930f9dc89b3942e0f9c99ac823e32fedc6148102e8450cd60e98f", "sourceVerificationStatus": "unverified", "citationTargets": [ "section:2", "section:6.1" ] } ], "legacyCompatibility": [ { "label": "FASS – Varivax, produktresumé", "url": "https://www.fass.se/health/product/20040607000762/smpc" }, { "label": "Adda – upphandling av vattkoppsvaccin", "url": "https://www.adda.se/upphandling-och-ramavtal/planerade-och-pagaende-upphandlingar/vaccin-enligt-det-nationella-barnvaccinationsprogrammet-2025---vattkoppor/" } ] }, "fieldMatrix": [ { "field": "identity", "layer": "identity", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "summary", "layer": "editorial", "source": "editorial", "status": "EDITORIAL_ONLY", "blocker": null }, { "field": "facts", "layer": "structured-fact", "source": "legacy-compatibility", "status": "LEGACY_COMPATIBILITY", "blocker": "Kvarvarande legacy-rader saknar ännu en kanonisk faktarad bunden till SourceVersion + CitationTarget. De behåller sin egen fältkälla och promotas inte." }, { "field": "canonicalFacts", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "regulatoryIndication", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "documents", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "programme", "layer": "structured-fact", "source": "canonical", "status": "CANONICAL_READY", "blocker": null }, { "field": "publication", "layer": "publication-policy", "source": "editorial", "status": "EDITORIAL_ONLY", "blocker": null } ] } } ] }